$0.4M supported data analysis of rhesus animal model and grant to gain understanding of the
host pathways that regulate viral gene expression and viral subversion of the host immune
system.

$0.1M funded vaccine development at VRC and DIR

 

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, March 6, 2020 5:31 PM

To: Fauci, Anthony (NIH/NIAID) [E]E 8) 6] >; Auchincloss, Hugh (NIH/NIAID) [E]
CC >; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
(NIH/NIAID) (E€] [______, ©) @)>; Harper, Jill (NIH/NIAID) [E] [—____®) @)v>;
Crum, Wayne (NIH/NIAID) [EJF

Cc: Eisinger, Robert (NIH/NIAID) (C0) >; Folkers, Greg (NIH/NIAID) [E]
Cc CC=*#€bY >; Conrad, Patricia (NIH/NIAID) (EJZ 8) J; Marston,
Hilary (NIH/NIAID) or. Lerner, Andrea (NIH/NIAID) [E]
CCC (J; Dolepel, Laurie (NIH/NIAID) (EJ[ YF Gilles, Sharon
(NIH/NIAID) (E][—_________@) @)>; Routh, Jennifer (NIH/NIAID) [E][—______ ©) ©.
Stover, Kathy (NIH/NIAID) [E] EY; Law, Kim (NIH/NIAID) [E] E>;
Lee, Kun-Lin (NIH/NIAID) [EI~ OF

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/5/20

 

 

Tony,

Since we our last report we have increased spending on the COVID-19 response by $0.2M for a
total YTD spending of $12.6M.

The $0.2M increase is for vaccine candidate development at NIAID Intramural Labs including
RML. Costs are mostly for staffing and overhead and include a preclinical immunogenicity
